Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Slides:

Advertisements

Similar presentations

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Advertisements

The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa.

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Intravenous antibiotics given for 2 weeks do not eradicate persistent Staphylococcus aureus clones in cystic fibrosis patients C. Andersen, B.C. Kahl,

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis Mohamed Zebouh, Caroline Thomas,

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment Winnie Ridderberg, Karen E.M.

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

E. M. Westerman, A. H. De Boer, P. P. H. Le Brun, D. J. Touw, A. C

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Lack of evidence of increased risk of bacterial transmission during cystic fibrosis educational programmes Winnie Ridderberg, Camilla Andersen, Michael.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

The ease of breathing test tracks clinical changes in cystic fibrosis

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Piperacillin/tazobactam continuous infusion at 12G/1

A.H. Gifford Journal of Cystic Fibrosis

Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure I.J. Clifton, A.M. Morton, N.S. Ambrose,

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis C.S. Dalbøge, X.C. Nielsen, K. Dalhoff,

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Antine E. Stenbit, Wendy M. Bullington, Julie L. Heh, Patrick A. Flume

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby, S. Jensen-Fangel, H.V. Olesen, M. Skov, L.E. Lemming, T. Pressler, H.K. Johansen, N. Nørskov-Lauritsen Journal of Cystic Fibrosis Volume 12, Issue 6, Pages 638-643 (December 2013) DOI: 10.1016/j.jcf.2013.04.013 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Cumulative proportion of patients who remained free of Achromobacter in relation to initial treatment with inhaled antimicrobials. Solid line, patients treated with inhaled ceftazidime, colistin or tobramycin (N=25); dotted line, patients not receiving initial treatment with inhaled antimicrobials (N=22). Log rank p value<0.01. Journal of Cystic Fibrosis 2013 12, 638-643DOI: (10.1016/j.jcf.2013.04.013) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions